Business, energy, technology, markets and global industry news from Business News Today

Hantavirus

PharmaDeviceNews Hantavirus
Pharma & Biotech

Could Hyundai Bioscience’s XAFTY become a crisis-response antiviral for Ebola and hantavirus?

Ebola urgency is rising, but broad-spectrum antivirals still face a proof gap. Hyundai Bioscience’s XAFTY now enters that debate.

Read More
Representative image: Traws Pharma’s push into potential hantavirus treatment candidates highlights the growing need for antiviral drug development against rare but severe rodent-borne viral infections.
Pharma & Biotech

Can Traws Pharma turn hantavirus urgency into a credible antiviral program?

Hantavirus has no specific antiviral option. Traws Pharma’s next test is turning outbreak urgency into credible clinical candidates.

Read More